Innocare Pharma Inc.

2 trials 1 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

0 Completed trials

6 Countries active

4 Unique IMPs

N/A Results reported

Phase III

Phase II

Phase III: 1 Phase II: 1

Top indications

Mantle cell lymphoma 1

Top IMPs

3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-METHYLHEXAHYDROPYRROLO[3,4-C]PYRROL-2(1H)-YL]-3-OXOPROPANENITRILE 1 BENDAMUSTINE HYDROCHLORIDE 1 ORELABRUTINIB 1 RITUXIMAB 1

All trials

2 total

A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending

2025-524241-27-00 Phase III 2 countries BENDAMUSTINE HYDROCHLORIDE; ORELABRUTINIB; RITUXIMAB
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri… Recruiting

2025-523404-74-00 Phase II 5 countries 3-[(3AS,6AR)-5-{5-CHLORO-2-[(1-METHYL-1H-PYRAZOL-4-YL)AMINO]PYRIMIDIN-4-YL}-3A-M…

Showing 1–2 of 2 trials

← All sponsors A–Z